Related Experiment Videos
Metastatic disease in the breast.
1Atatürk University Medical Faculty, Department of General Surgery, PK 18, Erzurum 25171, Turkey. mnakcay@atauni.edu.tr
Breast (Edinburgh, Scotland)
|February 18, 2004
Summary
Metastatic breast cancer, rare but unexpected, often mimics primary tumors. Diagnosis via fine-needle aspiration cytology is crucial for appropriate treatment and avoiding unnecessary surgery.
Area of Science:
- Oncology
- Radiology
- Pathology
Background:
- Metastatic involvement of the breast is uncommon, often presenting as an unexpected diagnosis in women with breast masses.
- The most frequent cause is contralateral breast carcinoma, followed by malignant melanoma, lymphoma, lung, ovarian, and other solid tumors.
- Clinical symptoms like pain or discharge are unusual; solitary lesions are most common.
Purpose of the Study:
- To review the characteristics and diagnostic approaches for metastatic breast disease.
- To highlight the importance of differentiating metastatic breast cancer from primary breast cancer.
- To emphasize the role of fine-needle aspiration cytology in diagnosis and treatment planning.
Main Methods:
- Review of literature on metastatic breast cancer.
- Analysis of clinical presentations, mammographic findings, and diagnostic modalities.
- Emphasis on fine-needle aspiration cytology (FNAC) and open biopsy.
Main Results:
- Common sources of breast metastases include contralateral breast cancer, melanoma, lymphoma, lung, and ovarian cancers.
- Mammographic findings can resemble primary breast cancer but are often multiple, bilateral, and round with defined margins.
- Fine-needle aspiration cytology is effective in distinguishing metastases from primary tumors.
Conclusions:
- Metastatic breast cancer requires accurate diagnosis to guide appropriate chemotherapy and radiotherapy.
- Fine-needle aspiration cytology plays a vital role in avoiding unnecessary mastectomy and ensuring correct management.
- Early and accurate diagnosis improves patient outcomes by enabling targeted oncological therapies.